Copyright 2006-2010 Abiant, Inc.
Imaging Experience
Full Clinical Studies
   
 
Therapeutic Class
Compounds
Objectives
  Mood disorders
Buspirone
Acute, Steady state, Washout profile
    Paroxetine and other SSRI, SNRI
compounds
Comparative effects upon regional glucose
metabolism
    CRF1 targeted compound
Central effect, dose response
    NK1 targeted compounds
Dose response, therapeutic and side effect
profiles; comparison of two pipeline
compounds
    Novel receptor targeted cmpd
Central effect at multiple time points; dose
response
  Sedative anxiolytic
Lorazepam
Central effect; comparison of active and
neutral tasks during uptake
  Sedative-hypnotic
Zolpidem
Comparison to a pipeline compound
  Epilepsy / Pain
Gabapentin
Comparison to a pipeline compound
  Other GABA modulator
Voltage gated Ca++ channel
targeted cmpd
Central effect; comparison to known drugs
  Attention Deficit Disorder
Methylphenidate
Central effect; effect of task during FDG
uptake
  Schizophrenia
Cmpd targeted at novel receptor
Central effect, dose response
  Other
Cmpd targeted at novel receptor
Biodistribution
    Cmpd targeted at novel receptor
Central effect, dose response
  Non-CNS drugs
Tolteradine
Selective muscarinic targeted cmpd
Comparison of side effect profiles
We have successfully conducted imaging studies on
a comprehensive array of CNS and non-CNS
compounds including listed below.  In particular, we
have demonstrated a unique ability to obtain data on
novel compounds for which a receptor specific ligand
reference compound data to which novel drug effects
can be compared.

Below are examples of clinical studies and data
analyses we have conducted.
Abiant, Inc.  480 West Center Street, Suite 202, Grayslake, Illinois  60030
Full Preclinical Studies
 
 
Species
PET Tracer
Objectives
  Rhesus macaque
C11-labeled novel compound
Biodistribution
  Rhesus macaque
DASB
DASB uptake measurement
  Rhesus macaque
FDG
Effect of ketamine upon glucose metabolism
measurement
Comparison of the glucose metabolic effects
of two acute doses of a novel compound
targeting the NK1 receptor system.
Data QC and Analysis
 
 
 
Study
Compound or Disease State
Analyses
  All clinical and preclinical
studies listed under Full Studies
Multiple
Data quality control and outlier identification,
region of interest analysis, SPM, Multivariate
Analysis
  Multi-site receptor occupancy
studies
Multiple
Data quality control, receptor occupancy
calculation, reporting, archival
  ADNI
Normal, MCI, AD, converters
at baseline  (> 300 subjects)
Region of interest, SPM, Multivariate analyses
of cross-class comparisons, correlations to
other biomarkers
  ADNI
Normal, MCI, AD longitudinal
progression:  FDG PET, 11C-PIB
Region of interest, SPM, Multivariate analysis
  ADNI
MCI sub-classification according to
clinical progression (> 400 scans)
Region of interest, Multivariate analysis,
correlations to cognitive data, other
biomarkers
  Multi-site
Normal, AD, Frontotemporal dementia
correlations to cognitive data and other
biomarkers
  Preclinical data
Novel receptor targeted compound
Translation of 2D data to 3D volumetric data
for SPM analyses
Drug Evaluation...